Our Advisors
-
To be announced
Former Global Head of Healthcare Investment Research at Morgan Stanley
-
Elsy Boglioli Hofman
Currently Chair of Threefrog Therapeutics, Chief Executive Officer of Bio-Up and Advisor at Bluestone Venture Partners LLC. She is also on the board of Inova Software SA, Gensight Biologics SA, OSE Immunotherapeutics SA and Metafora Biosystems SAS.
Previously, she was Chief Operating Officer of Cellectis SA and a Managing Director & Partner at the Boston Consulting Group (BCG), where she was leading the biopharma business across Europe.
Elsy Boglioli Hofman received an undergraduate degree from Ecole Polytechnique and a graduate degree from Universitat Pompeu Fabra.
-
Jean Michel Deligny
Jean-Michel has over 30 years’ experience as a corporate finance adviser working with leading European technology companies.
He currently is Chairman of the Selection Committee at EIC ScalingUp, an acceleration programme funded by the European Innovation Council (EIC) Fund, one of Europe’s largest investors in deeptech technology. He is also Chairman of Inbolt, and sits on the Board of SiPearl and the advisory board of Letts Group .
In addition, Jean-Michel is a Senior Advisor to Silverpeak, the technology investment banking boutique he co-founded in 2015.
Before that, he was the European Head of Technology Investment Banking at UBS.
Jean-Michel holds an MBA from Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) business school in Paris.
-
Dr Ali Hasan
Chief Medical and Healthcare Officer at Vitality, leading a diverse team of ~140 responsible for design and spend of primary, secondary, and digital healthcare.
Associate Non-executive Director at the Care Quality Commission (England's Regulator of Health and Social Care).
Non-executive Director at Healthcode (UK SaaS company processing over £3billion worth of transactions per year).
Non-executive Director at HPA (JV with Aviva PLC).
Independent advisor to a number of earlier stage companies in digital health, diagnostics, AI and deep technology, and other areas.
Previously physician in the NHS, consultant at McKinsey & Company, and has held several other non-executive and operator roles.
-
Massimo Portincaso
Massimo is the Founder and Managing Partner at DeepWave Ventures, Founder of Officinae Bio, a breakthrough biotechnology company. Massimo is also Senior Advisor and Board Member to multiple biotechnology Start-ups & Growth companies (Senior Advisor at Insempra, Chairman at ATLANT 3D Nanosystems, Board Member at ZERO Vertical Farms) and advisor to multiple venture capital and growth funds and to VeniSIA.
Former Partner and Managing Director at the Boston Consulting Group (BCG), where he co-founded and built the global Deep Tech practice and ran the marketing function for more than a decade.
Conducted the strategic and technology due diligence of a decacorn SPAC in synthetic biology
Chairman of Hello Tomorrow, a global organization that aims to accelerate the adoption of Deep Technologies
Thought-leader and author on deep tech and nature co-design. His work has been featured in Harvard Business Review, and the Journal of Venture Capital, amongst others.
-
Julien Nicod
20+ years of investment/advisory experience
Senior Advisor to PLUM Acquisition Corp I (NASDAQ: PLMI ) a $375m DeepTech-focused investment vehicle, recently merged with a US-based transformative additive manufacturing & solid-state battery company.
Senior Advisor (Deal origination) to several leading international private equity firms (growth & buyouts, targets within $750m-$2.5bn EV, in highly-regulated industries, and adjacent markets)
Senior Advisor to Health Ventures, a Single-Family Office backed by a serial Life Sciences entrepreneur and executive. Senior Advisor to several other international Single Family Offices (undisclosed), focused on deal origination and co-investment syndication.
Multi-strategy/-asset investment experience, across the company structure. Sector/geography agnostic.
Investor and shareholder across a range of businesses, geographies and stages, from early-stage to late-stage, across industrials, healthcare, energy, and technology. Investor, Shareholder and interim Management team member of a couple of disruptive early-stage healthcare & life sciences companies.